---
layout: default
title: Allopurinol
description: "Allopurinol çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 16
evidence_level: L4
indication_count: 10
---

# Allopurinol

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Allopurinolï¼šå¾ç—›é¢¨æ²»ç™‚åˆ°è‚è‡Ÿèˆ‡ä»£è¬ç–¾ç—…çš„æ½›åœ¨æ‡‰ç”¨

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Allopurinol å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Allopurinol æ˜¯ç¶“å…¸çš„é»ƒå˜Œå‘¤æ°§åŒ–é…¶æŠ‘åˆ¶åŠ‘ï¼Œä¸»è¦ç”¨æ–¼ç—›é¢¨å’Œé«˜å°¿é…¸è¡€ç—‡æ²»ç™‚ï¼ŒTxGNN é æ¸¬å…¶å¯èƒ½å°è‚æ€§ç´«è³ªç—‡åŠè‹¯ä¸™èƒºé…¸ä»£è¬ç•°å¸¸æœ‰æ½›åœ¨ç™‚æ•ˆã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | ç—›é¢¨ç—‡ã€ç—›é¢¨æ€§é—œç¯€ç‚ã€å°¿é…¸çµçŸ³ã€é«˜å°¿é…¸è¡€ç—‡ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | hepatic porphyriaã€hepatoportal sclerosisã€primitive portal vein thrombosisã€idiopathic copper-associated cirrhosisã€early-onset familial noncirrhotic portal hypertensionã€hepatopulmonary syndromeã€disorder of phenylalanine metabolismã€goutã€immune-mediated necrotizing myopathyã€antisynthetase syndrome |
| TxGNN é æ¸¬åˆ†æ•¸ | 0.999ï¼ˆè‚æ€§ç´«è³ªç—‡ï¼‰ã€0.999ï¼ˆè‹¯ä¸™èƒºé…¸ä»£è¬ç•°å¸¸ï¼‰ |
| è­‰æ“šç­‰ç´š | L3ï¼ˆæœ‰æ–‡ç»æ”¯æŒï¼‰ |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 125 å¼µ |
| å»ºè­°æ±ºç­– | Explore |





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. hepatic porphyria</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.95%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Allopurinol æ˜¯é»ƒå˜Œå‘¤æ°§åŒ–é…¶ï¼ˆXOï¼‰æŠ‘åˆ¶åŠ‘ï¼Œä¸»è¦ä½œç”¨æ˜¯æ¸›å°‘å°¿é…¸ç”Ÿæˆã€‚ç„¶è€Œï¼Œå…¶ä»£è¬ä½œç”¨é ä¸æ­¢æ–¼æ­¤ï¼š</p>

<p><strong>é æ¸¬çš„æ©Ÿè½‰é€£çµï¼š</strong></p>

<ol>
<li><strong>è‚æ€§ç´«è³ªç—‡ï¼ˆHepatic Porphyriaï¼‰</strong>ï¼šç´«è³ªç—‡æ˜¯ä¸€ç¨®å½±éŸ¿è¡€ç´…ç´ åˆæˆçš„ä»£è¬ç–¾ç—…ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œallopurinol å¯èƒ½é€šéæŠ‘åˆ¶è‰²èƒºé…¸ 2,3-é›™åŠ æ°§é…¶ï¼ˆTDOï¼‰å°è¡€ç´…ç´ çš„åˆ©ç”¨ï¼Œé–“æ¥ä¿è­·èª¿ç¯€æ€§è¡€ç´…ç´ æ± ï¼Œå¾è€Œæ¸›å°‘ 5-ALA åˆæˆé…¶çš„èª˜å°ã€‚é€™ä¸€å‡èªªåœ¨å‹•ç‰©å¯¦é©—ä¸­å¾—åˆ°æ”¯æŒã€‚</li>

<li><strong>è‹¯ä¸™èƒºé…¸ä»£è¬ç•°å¸¸</strong>ï¼šAllopurinol çš„æ´»æ€§ä»£è¬ç‰© oxypurinol åœ¨é«”å…§æœ‰å»£æ³›çš„ä»£è¬ä½œç”¨ï¼Œå¯èƒ½å½±éŸ¿å¤šç¨®èƒºåŸºé…¸ä»£è¬é€”å¾‘ã€‚</li>
</ol>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>ç›®å‰ç„¡é‡å°æ­¤ç‰¹å®šé©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚</p>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31443750/" target="_blank">31443750</a></td><td>2019</td><td>Article</td><td>Medical hypotheses</td><td>Hypothesis: Metabolic targeting of 5-aminolevulinate synthase by tryptophan and ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1567472/" target="_blank">1567472</a></td><td>1992</td><td>Article</td><td>Biochemical pharmacology</td><td>Effects of acute carbamazepine administration on haem metabolism in rat liver.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. hepatoportal sclerosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. primitive portal vein thrombosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. idiopathic copper-associated cirrhosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. early-onset familial noncirrhotic portal hypertension</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. hepatopulmonary syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. disorder of phenylalanine metabolism</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ7 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/799549/" target="_blank">799549</a></td><td>1976</td><td>Article</td><td>Clinical pharmacokinetics</td><td>Pharmacologically active drug metabolites: therapeutic and toxic activities, pla...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39156502/" target="_blank">39156502</a></td><td>2024</td><td>Article</td><td>World journal of gastroenterol</td><td>Leech Poecilobdella manillensis protein extract ameliorated hyperuricemia by res...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18694741/" target="_blank">18694741</a></td><td>2008</td><td>Article</td><td>Chemico-biological interaction</td><td>Lithospermic acid as a novel xanthine oxidase inhibitor has anti-inflammatory an...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/851118/" target="_blank">851118</a></td><td>1977</td><td>Article</td><td>The American journal of medici</td><td>Active drug metabolites and renal failure.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22932763/" target="_blank">22932763</a></td><td>2012</td><td>Article</td><td>Molecular bioSystems</td><td>Metabolite target analysis of human urine combined with pattern recognition tech...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11729361/" target="_blank">11729361</a></td><td>2001</td><td>Article</td><td>Pharmacology</td><td>Effects of diacerein on indomethacin-induced gastric ulceration.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2853054/" target="_blank">2853054</a></td><td>1988</td><td>Article</td><td>European journal of clinical p</td><td>Allopurinol prevents ischaemia-dependent haemorheological changes.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. immune-mediated necrotizing myopathy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.86%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. antisynthetase syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.85%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. inflammatory myopathy with abundant macrophages</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.85%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å…§è¡›è—¥è£½å­—ç¬¬001595è™Ÿ | äºèƒ½æœ—è† å›Š | è† å›ŠåŠ‘ | ç—›é¢¨ç—‡ã€ç—›é¢¨æ€§é—œç¯€ç‚ã€å°¿é…¸çµçŸ³ã€é«˜å°¿é…¸è¡€ç—‡ |
| è¡›ç½²è—¥è£½å­—ç¬¬016713è™Ÿ | å„ªè‰¯ç—›é¢¨èµ°éŒ  | éŒ åŠ‘ | åŒä¸Š |
| è¡›ç½²è—¥è£½å­—ç¬¬020894è™Ÿ | æè¼å¨å¯§ç–¼éŒ  | éŒ åŠ‘ | åŒä¸Š |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬026629è™Ÿ | ç•°å˜Œå‘¤é†‡ | åŸæ–™è—¥ | æ²»ç—›é¢¨è—¥ |

**è¨±å¯è­‰æŒæœ‰è€…**ï¼šæ°¸ä¿¡è—¥å“ã€å„ªè‰¯åŒ–å­¸è£½è—¥ã€æè¼è—¥å“ç­‰å¤šå®¶

## å®‰å…¨æ€§è€ƒé‡

- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼š
  - Aluminum hydroxideï¼ˆä¸­åº¦ï¼‰
  - Amoxicillinï¼ˆè¼•åº¦ï¼‰
  - Sucralfateï¼ˆä¸­åº¦ï¼‰
  - Chlorpropamideï¼ˆè¼•åº¦ï¼‰

- **é‡è¦è­¦èª**ï¼š
  - åš´é‡çš®è†šéæ•åæ‡‰ï¼ˆSJS/TENï¼‰é¢¨éšªï¼Œå°¤å…¶æ˜¯ HLA-B*5801 åŸºå› å‹æ”œå¸¶è€…
  - è…åŠŸèƒ½ä¸å…¨æ‚£è€…éœ€èª¿æ•´åŠ‘é‡
  - åœ¨å°ç£ï¼Œå»ºè­°é«˜é¢¨éšªæ—ç¾¤é€²è¡ŒåŸºå› æª¢æ¸¬

å®‰å…¨æ€§è³‡è¨Šè«‹åƒè€ƒåŸå» ä»¿å–®ã€‚


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Bone Marrow Failure Disorders** ğŸŸ¡ Moderate
- é¢¨éšªåŒ…æ‹¬ï¼šéª¨é«“æŠ‘åˆ¶ã€‚

**Dehydration** ğŸŸ¡ Moderate
- å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šExplore**

**ç†ç”±ï¼š**
Allopurinol å°è‚æ€§ç´«è³ªç—‡çš„é æ¸¬æœ‰åˆæ­¥çš„æ©Ÿè½‰å‡èªªæ”¯æŒï¼Œä½†è‡¨åºŠè­‰æ“šä»ç„¶æœ‰é™ã€‚è€ƒé‡åˆ°é€™æ˜¯ä¸€ç¨®è€è—¥ï¼Œå®‰å…¨æ€§è³‡æ–™å®Œæ•´ï¼Œä¸”åƒ¹æ ¼ä½å»‰ï¼Œå€¼å¾—é€²ä¸€æ­¥æ¢ç´¢ã€‚ç„¶è€Œï¼Œè‚æ€§ç´«è³ªç—‡æ˜¯ç½•è¦‹ç–¾ç—…ï¼Œè‡¨åºŠè©¦é©—è¨­è¨ˆå…·æœ‰æŒ‘æˆ°æ€§ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- æ›´å¤šå‹•ç‰©å¯¦é©—é©—è­‰æ©Ÿè½‰
- èˆ‡è‚æ€§ç´«è³ªç—‡å°ˆå®¶åˆä½œé€²è¡Œæ¦‚å¿µé©—è­‰ç ”ç©¶
- è€ƒé‡ compassionate use æˆ–å€‹æ¡ˆå ±å‘Šæ”¶é›†
- æ³¨æ„ SJS/TEN é¢¨éšªï¼Œå°¤å…¶åœ¨äºæ´²äººç¾¤ä¸­

**ç‰¹åˆ¥æ³¨æ„ï¼š**
åœ¨å°ç£ä½¿ç”¨ allopurinol å‰ï¼Œæ‡‰è€ƒæ…®é€²è¡Œ HLA-B*5801 åŸºå› æª¢æ¸¬ä»¥é™ä½åš´é‡çš®è†šåæ‡‰é¢¨éšªã€‚

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Alirocumab]({{ "/drugs/alirocumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Polyethylene Glycol 400]({{ "/drugs/polyethylene_glycol_400/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Alprostadil]({{ "/drugs/alprostadil/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Ibuprofen]({{ "/drugs/ibuprofen/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Naphazoline]({{ "/drugs/naphazoline/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Allopurinolè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/allopurinol/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_allopurinol,
  title = {Allopurinolè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/allopurinol/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
